Comparable effect of prostaglandin E1 in decreasing in vivo platelet deposition on human lesion sites after intravenous and intraarterial application.
It had been claimed that prostaglandin E1 is degraded during first lung passage to a major extent. Clinical results, however, as well as various platelet function tests and coagulation parameters revealed no apparent difference after i.v. and i.a. infusion. Thus, we examined the question what the quantitative difference between i.v. and i.a. PGE1-application would be upon in-vivo platelet function assessed by platelet uptake over active lesion sites as well as platelet half-life monitoring after autologous 111-In-oxine platelet labelling. In patients suffering from peripheral vascular disease stage II according to Fontaine PGE1 was able to decrease platelet uptake after i.v. and i.a. therapy to a comparable extent; similarily, a significant prolongation in platelet half-life was noted, again revealing no difference. As the decrease in platelet uptake is assumed to be predominantly a vascular effect, it is hypothetized that more stable derivatives of PGE1 are active, counterbalancing a lower biological activity with a longer half-life.
Sinzinger
H
H
Department of Nuclear Medicine, University of Vienna, Austria.
O'Grady
J
J
Fitscha
P
P
Rauscha
F
F
Kaliman
J
J
D000527:Alprostadil / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D001161:Arteriosclerosis / Q000097:blood*; D001792:Blood Platelets / Q000378:metabolism*; D006207:Half-Life; D006801:Humans; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous; D008099:Liver / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects*; D013154:Spleen / Q000187:drug effects
D000527:Alprostadil